Literature DB >> 2164223

Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity.

P A Sherman1, J A Fyfe.   

Abstract

The human immunodeficiency virus (HIV) integration protein, a potential target for selective antiviral therapy, was expressed in Escherichia coli. The purified protein, free of detectable contaminating endonucleases, selectively cleaved double-stranded DNA oligonucleotides that mimic the U3 and the U5 termini of linear HIV DNA. Two nucleotides were removed from the 3' ends of both the U5 plus strand and the U3 minus strand; in both cases, cleavage was adjacent to a conserved CA dinucleotide. The reaction was metal-ion dependent, with a preference for Mn2+ over Mg2+. Reaction selectivity was further demonstrated by the lack of cleavage of an HIV U5 substrate on the complementary (minus) strand, an analogous substrate that mimics the U3 terminus of an avian retrovirus, and an HIV U5 substrate in which the conserved CA dinucleotide was replaced with a TA dinucleotide. Such an integration protein-mediated cleavage reaction is expected to occur as part of the integration event in the retroviral life cycle, in which a double-stranded DNA copy of the viral RNA genome is inserted into the host cell DNA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164223      PMCID: PMC54273          DOI: 10.1073/pnas.87.13.5119

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  A 32,000-dalton nucleic acid-binding protein from avian retravirus cores possesses DNA endonuclease activity.

Authors:  D P Grandgenett; A C Vora; R D Schiff
Journal:  Virology       Date:  1978-08       Impact factor: 3.616

2.  Lac repressor-operator interaction. I. Equilibrium studies.

Authors:  A D Riggs; H Suzuki; S Bourgeois
Journal:  J Mol Biol       Date:  1970-02-28       Impact factor: 5.469

3.  The retrovirus pol gene encodes a product required for DNA integration: identification of a retrovirus int locus.

Authors:  A T Panganiban; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

4.  Selective cleavage in the avian retroviral long terminal repeat sequence by the endonuclease associated with the alpha beta form of avian reverse transcriptase.

Authors:  G Duyk; J Leis; M Longiaru; A M Skalka
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

5.  The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration.

Authors:  M Katzman; R A Katz; A M Skalka; J Leis
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

6.  Avian retrovirus pp32 DNA-binding protein. I. Recognition of specific sequences on retrovirus DNA terminal repeats.

Authors:  T K Misra; D P Grandgenett; J T Parsons
Journal:  J Virol       Date:  1982-10       Impact factor: 5.103

7.  Interaction of int protein with specific sites on lambda att DNA.

Authors:  W Ross; A Landy; Y Kikuchi; H Nash
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

8.  Virus-coded origin of a 32,000-dalton protein from avian retrovirus cores: structural relatedness of p32 and the beta polypeptide of the avian retrovirus DNA polymerase.

Authors:  R D Schiff; D P Grandgenett
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

9.  A mutant murine leukemia virus with a single missense codon in pol is defective in a function affecting integration.

Authors:  L A Donehower; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

10.  Construction and analysis of deletion mutations in the pol gene of Moloney murine leukemia virus: a new viral function required for productive infection.

Authors:  P Schwartzberg; J Colicelli; S P Goff
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

View more
  176 in total

Review 1.  Retroviral DNA integration.

Authors:  P Hindmarsh; J Leis
Journal:  Microbiol Mol Biol Rev       Date:  1999-12       Impact factor: 11.056

2.  Substrate sequence selection by retroviral integrase.

Authors:  H Zhou; G J Rainey; S K Wong; J M Coffin
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation.

Authors:  Y Hwang; D Rhodes; F Bushman
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

4.  Monoclonal antibodies against the minimal DNA-binding domain in the carboxyl-terminal region of human immunodeficiency virus type 1 integrase.

Authors:  T Ishikawa; N Okui; N Kobayashi; R Sakuma; T Kitamura; Y Kitamura
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Repair of gaps in retroviral DNA integration intermediates.

Authors:  K E Yoder; F D Bushman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Retroviral cDNA integration: stimulation by HMG I family proteins.

Authors:  L Li; K Yoder; M S Hansen; J Olvera; M D Miller; F D Bushman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes.

Authors:  K Gao; S L Butler; F Bushman
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

8.  Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection.

Authors:  L Li; J M Olvera; K E Yoder; R S Mitchell; S L Butler; M Lieber; S L Martin; F D Bushman
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

9.  Characterization of a replication-defective human immunodeficiency virus type 1 att site mutant that is blocked after the 3' processing step of retroviral integration.

Authors:  H Chen; A Engelman
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2+-dependent DNA integration in vitro.

Authors:  S Carteau; S C Batson; L Poljak; J F Mouscadet; H de Rocquigny; J L Darlix; B P Roques; E Käs; C Auclair
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.